Galectin Therapeutics Inc.
GALT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.00 | 0.22 | 0.10 | -0.30 |
| FCF Yield | -1.30% | -4.93% | -9.97% | -15.80% |
| EV / EBITDA | 0.00 | -42.26 | -22.55 | -16.82 |
| Quality | ||||
| ROIC | 0.00% | -94.77% | 190.84% | -385.72% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.43 | 0.88 | 0.80 | 1.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 46.35% | 14.14% | 39.89% | -49.81% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -18.75 | -12.77 | -8.91 |
| Interest Coverage | 0.00 | -2.53 | -4.53 | -7.20 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -263,925.00 | -58,806.00 | -28,280.00 |